Peptic ulcer bleeding following therapeutic endoscopy: A new indication for intravenous esomeprazole

Reviews in Gastroenterological Disorders

Volumn 9, Issue 4, 2009, Pages

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Esomeprazole; Gastroesophageal reflux disease; Peptic ulcer bleeding; Proton pump inhibitor

Indexed keywords

AMPICILLIN DERIVATIVE; ATAZANAVIR; DIAZEPAM; ESOMEPRAZOLE; IRON SALT; KETOCONAZOLE; LANSOPRAZOLE; NELFINAVIR; PANTOPRAZOLE; PENICILLIN G; RITONAVIR PLUS SAQUINAVIR; VORICONAZOLE; WARFARIN; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DYSPEPSIA; ENDOSCOPIC THERAPY; FLATULENCE; GASTRIC HYPERACIDITY; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PEPTIC ULCER BLEEDING; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; TREATMENT OUTCOME; BIOAVAILABILITY; DRUG INTERACTION; GASTROINTESTINAL ENDOSCOPY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; OMEPRAZOLE; PEPTIC ULCER HEMORRHAGE; PROTON PUMP INHIBITORS; RECURRENCE;

EID: 77950476358     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: 10.3909/rigd0349     Document Type: Review

References (33)

1. Center for Drug Evaluation and Research, Food and Drug Administration. Esomeprazole sodium, Application #021689. Orange book: approved drug products with therapeutic equivalence evaluations, 2009. Available at: http://www.fda. gov/cder/ob/default.htm. Accessed February 10, 2009.
2. Center for Drug Evaluation and Research, Food and Drug Administration. Drugs FDA Approved Drug Products, 2009. Available at: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed February 10, 2009.
3. AstraZeneca submits sNDA for Nexium® I.V. for peptic ulcer bleed indication [press release]. Wilmington, DE: AstraZeneca LP. May 30, 2008. Available at: http://www.astrazeneca-us.com/ search/?itemId=2932273. Accessed February 10, 2009.
4. Nexium® I.V. (esomeprazole sodium) for injection [package insert]. Wilmington, DE: AstraZeneca LP; 2009. Available at: http://www1.astrazenecaus. com/pi/nexium-iv.pdf. Accessed February 10, 2009.
5. Prevacid® I.V. (lansoprazole) for injection [package insert]. Chicago, IL: Takeda Pharmaceuticals America, Inc.; 2008. Available at: http://pitap. abbott.com/prevacidiv.pdf?noCache=. Accessed February 10, 2009.
6. Protonix® I.V. (pantoprazole sodium) for injection [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2007. Available at: http://www.wyeth.com/content/showlabeling.asp?id=469. Accessed February 10, 2009.
7. Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol. 2006; 101:945-953.
8. Kang JY, Elders A, Majeed A, et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther. 2006;24:65-79.
9. Soplepmann J, Peetsalu A, Peetsalu M, et al. Peptic ulcer haemorrhage in Tartu County, Estonia: epidemiology and mortality risk factors. Scand J Gastroenterol. 1997;32: 1195-1200.
10. Thomsen RW, Riis A, Christensen S, et al. Diabetes and 30-day mortality from peptic ulcer bleeding and perforation: a Danish population-based cohort study. Diabetes Care. 2006;29: 805-810.
11. Mose H, Larsen M, Riis A, et al. Thirty-day mortality after peptic ulcer bleeding in hospitalized patients receiving low-dose aspirin at time of admission. Am J Geriatr Pharmacother. 2006; 4:244-250.
12. Jensen DM. Current diagnosis and treatment of severe ulcer hemorrhage. ASGE Clin Update. 1999;6:1-4.
13. Lin HJ, Lo WC, Lee FY, et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med. 1998;158:54-58.
14. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343:310-316.
15. Kovacs TO, Jensen DM. The short-term medical management of non-variceal upper gastrointestinal bleeding. Drugs. 2008;68:2105-2111.
16. Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med. 2008;359:928-937.
17. Elmunzer BJ, Young SD, Inadomi JM, et al. Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol. 2008;103:2625-2632.
18. Green FW Jr, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978;74:38-43.
19. Freston JW. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. Am J Med. 2004;117(suppl 5A): 14S-22S.
20. Nexium® (esomeprazole magnesium) [package insert]. Wilmington, DE: AstraZeneca LP; 2008. Available at: http://www1.astrazeneca-us.com/pi/Nexium. pdf. Accessed February 10, 2009.
21. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill Part 1: Pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother. 2005;39:1667-1677.
22. Keating GM, Figgitt DP. Intravenous esomeprazole. Drugs. 2004;64:875-882.
23. Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci. 2005;50:1185-1193.
24. Wong SKH, Yang GPC, Daniel CTM, et al. Oral vs intravenous infusion of esomeprazole on gastric acid suppression in patients with peptic ulcer disease - a randomized trial [abstract]. J Gastroenterol Hepatol. 2007(suppl 2);22:A188.
25. Wilder-Smith CH, Bondarov P, Lundgren M, et al. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur J Gastroenterol Hepatol. 2005;17:191-197.
26. Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol. 2000;56:665-670.
27. Wei KL, Tung SY, Sheen CH, et al. Effect of oral esomeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. J Gastroenterol Hepatol. 2007;22:43-46.
28. Sung JJY, Mössner J, Barkun A, et al. Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: rationale/design of Peptic Ulcer Bleed study. Aliment Pharmacol Ther. 2008;27:666-677.
29. Barkun A, Sung JJY, Kuipers JE, et al. Intravenous esomeprazole for prevention of peptic ulcer re-bleeding in a predominantly Caucasian population: results on clinical benefits and hospital resource use [abstract]. Presented at the 39th Nordic Meeting of Gastroenterology, June 4-6, 2008; Helsinki, Finland.
30. Sung JJY, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of peptic ulcer re-bleeding: a multinational, randomised, placebo-controlled study [abstract]. Presented at the 39th Nordic Meeting of Gastroenterology, June 4-6, 2008; Helsinki, Finland.
31. Barkun A, Adam V, Sung J, et al. The cost-effectiveness of high-dose intravenous esomeprazole in peptic ulcer bleeding - a U.S. cost perspective. Am J Gastroenterol. 2008;103(suppl 1):S48.
32. Andriulli A, Loperfido S, Focareta R, et al. Highversus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol. 2008;103:3011-3018.
33. Murthy S, Keyvani L, Leeson S, et al. Intravenous versus high-dose oral proton pump inhibitor therapy after endoscopic hemostasis of high-risk lesions in patients with acute nonvariceal upper gastrointestinal bleeding. Dig Dis Sci. 2007;52: 1685-1690.